RecruitingPhase 2NCT04430452

Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma

Studying Leukoencephalopathy with calcifications and cysts

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Mary Feng, MD
Principal Investigator
Mary Feng, MD
University of California, San Francisco
Intervention
Durvalumab(biological)
Enrollment
21 target
Eligibility
18 years · All sexes
Timeline
20222029

Study locations (1)

Collaborators

AstraZeneca

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04430452 on ClinicalTrials.gov

Other trials for Leukoencephalopathy with calcifications and cysts

Additional recruiting or active studies for the same condition.

See all trials for Leukoencephalopathy with calcifications and cysts

← Back to all trials